Cadrenal Therapeutics Says Late-Breaking Clinical Data On 12-Lipoxygenase Inhibitor, CAD-1005, Accepted For Oral Presentation At 34th Congress Of ISTH

Loading news article.

Cadrenal Therapeutics Says Late-Breaking Clinical Data On 12-Lipoxygenase Inhibitor, CAD-1005, Accepted For Oral Presentation At 34th Congress Of ISTH | WAPE

Cadrenal Therapeutics Says Late-Breaking Clinical Data On 12-Lipoxygenase Inhibitor, CAD-1005, Accepted For Oral Presentation At 34th Congress Of ISTH

Article summary

Related companies

Comments —